Human recombinant leptin ("metreleptin")
PreclinicalSmall molecule
Human recombinant leptin ("metreleptin") is one of 15 small molecule programs targeting Lipodystrophy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Lipodystrophy
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Ziagen
GSKApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Viracept
AAgouron Pharmaceuticals
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Viracept
AAgouron Pharmaceuticals
Approved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Myalept
Chiesi Farmaceutici S.p.A.Phase 3
EGRIFTA WR
TTheratechnologies
Phase 3
Ocaliva
IIntercept Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lipodystrophy1 trial
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
Completed·—·N/A·NCT01511016·17 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBaylor College of Medicine